RELATED STUDY
Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis.
Key Findings: The multi-target modulators of ECS could be able to control disease progression, and at the same time the symptoms of multiple sclerosis, and might have a translational potential and could represent promising candidates for clinical development.
Type of Study: Meta-analysis
Study Result: Positive
Study Location(s): Italy
Year of Pub: 2018
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), JWH-x Synthetic Cannabinoids, O-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Synthetic Cannabinoid (unspecified), Pharma THC, Pharma THC:CBD, Other Related Compounds
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype I, Chemotype II
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB1, CB2, PPAR - Gamma
Ligands Studied: Anti-inflammatory cytokines, Glutamate, Pro-inflammatory cytokines
